Cargando…

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions

Multiple Myeloma (MM) is a plasma cell tumor localized to the bone marrow (BM). Despite the fact that current treatment strategies have improved patients' median survival time, MM remains incurable. Epigenetic aberrations are emerging as important players in tumorigenesis making them attractive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alzrigat, Mohammad, Párraga, Alba Atienza, Agarwal, Prasoon, Zureigat, Hadil, Österborg, Anders, Nahi, Hareth, Ma, Anqi, Jin, Jian, Nilsson, Kenneth, Öberg, Fredrik, Kalushkova, Antonia, Jernberg-Wiklund, Helena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354653/ https://www.ncbi.nlm.nih.gov/pubmed/28052011 http://dx.doi.org/10.18632/oncotarget.14378

Ejemplares similares

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains
por: Alzrigat, Mohammad, et al.
Publicado: (2017)

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target
por: Agarwal, Prasoon, et al.
Publicado: (2016)

A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
por: Nylund, Patrick, et al.
Publicado: (2021)

Polycomb Target Genes Are Silenced in Multiple Myeloma
por: Kalushkova, Antonia, et al.
Publicado: (2010)

Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity
por: Alzrigat, Mohammad, et al.
Publicado: (2018)

The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma
por: Alzrigat, Mohammad, et al.
Publicado: (2017)

One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies
por: Kalushkova, Antonia, et al.
Publicado: (2021)

Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma
por: Jernberg-Wiklund, Helena, et al.
Publicado: (2012)

Outcome of COVID‐19 in multiple myeloma patients in relation to treatment
por: Susek, Katharina Helene, et al.
Publicado: (2020)

Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
por: Dimberg, Lina Y, et al.
Publicado: (2012)

Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment
por: Duvefelt, Charlotte Fristedt, et al.
Publicado: (2015)

Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry
por: Blimark, Cecilie Hveding, et al.
Publicado: (2018)

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
por: Nahi, Hareth, et al.
Publicado: (2019)

Potential value of pre-planned imaging of bone disease in multiple myeloma
por: Gundesen, Michael T., et al.
Publicado: (2023)

Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study
por: Wålinder, Göran, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
por: Moreau, Philippe, et al.
Publicado: (2019)

Dynamic follow‐up of smoldering multiple myeloma identifies a subset of patients at high risk of progression
por: Gran, Charlotte, et al.
Publicado: (2020)

Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma
por: Gran, Charlotte, et al.
Publicado: (2020)

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
por: Gregersen, Henrik, et al.
Publicado: (2021)

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
por: Wenthe, Jessica, et al.
Publicado: (2020)

Ras oncogene mutation in multiple myeloma
Publicado: (1989)

The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
por: Uttervall, Katarina, et al.
Publicado: (2014)

Oncogene addiction to c-MYC in myeloma cells
por: Holien, Toril, et al.
Publicado: (2012)

Conditioning with melphalan 200 mg/m(2) and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care
por: Afram, Gabriel, et al.
Publicado: (2022)

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
por: Duru, Adil Doganay, et al.
Publicado: (2015)

EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

T lymphocyte-mediated suppression of myeloma function in vitro. IV. Generation of effector suppressor cells specific for myeloma idiotypes
Publicado: (1982)

P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW.
por: Gundesen, Michael, et al.
Publicado: (2023)

The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression
por: Ali, Mina, et al.
Publicado: (2018)

SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma()()
por: Noll, Jacqueline E., et al.
Publicado: (2014)

MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment
por: Gu, Chunyan, et al.
Publicado: (2015)

Multiple mechanisms can disrupt oncogenic pathways in multiple myeloma
por: Hoang, Phuc H., et al.
Publicado: (2018)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
por: Pawlyn, C, et al.
Publicado: (2017)

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
por: Luo, Man (Melody), et al.
Publicado: (2020)

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma
por: Stamato, Maria Angelica, et al.
Publicado: (2017)

EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes
por: Harding, Taylor, et al.
Publicado: (2018)

Study on the Effect of EZH2 Inhibitor Combined with TIGIT Monoclonal Antibody against Multiple Myeloma Cells
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Cyclin K and cyclin D1b are oncogenic in myeloma cells
por: Marsaud, Véronique, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_a9kb3qf1nm8cpdih0s9cipn9vh